International Journal of Advanced Engineering Research and Science (IJAERS)
Peer-Reviewed Journal
ISSN: 2349-6495(P) | 2456-1908(O)
Vol-13, Issue-2; Feb, 2026
Journal Home Page Available: https://ijaers.com/
Article DOI: https://dx.doi.org/10.22161/ijaers.132.8

Evaluating the Effectiveness of Risk-Based Monitoring and Artificial Intelligence-Driven Strategies in Clinical Trial Management: A Data-Driven Analysis

Renjith Kathalikkattil Ravindran[1], Sharat Ragunayakula[2], Sanjay Kumar Polampally[3], Sreekumar Anjali Bhavan Vijayan[4], Ashok Morsu[5], Geeta Sandeep Nadella[6]

[1]Department of Computer Science, University of Calicut, India
Email: renjithkr@ieee.org
[2]College of Technology, Wilmington University, USA
Email : sharat.ragunayakula@ieee.org
[3]College of Nursing and Health Professions, Valparaiso University, USA
Email: spolampally@ieee.org
[4]SCMS School of Engineering and Technology, India
Email : sreevijayan@ieee.org
[5]School of Science and Computer Engineering, University of Houston-Clearlake, USA
Email: morsuashok@ieee.org
[6]School of Computer and Information Sciences, University of the Cumberlands, USA
Email : geeta.s.nadella@ieee.org

Received: 13 Jan 2026,

Received in revised form: 15 Feb 2026,

Accepted: 21 Feb 2026,

Available online: 26 Feb 2026

***Keywords*—Clinical Trails, Framework, Risk Based Monitoring (RBM), Kaggle, AI-Driven Framework.**

***Abstract*— This study investigates risk management practices in clinical trials by analyzing a dataset containing 1,000 trial records sourced from Kaggle's name is Clinical-Risk Management Dataset. The analysis based on their operational, regulatory, ethical, and financial risks are their comparative effectiveness of monitoring frameworks like traditional oversight, Risk-Based Monitoring (RBM), and AI-driven strategies. The findings are explored the trials experienced on average three adverse events is a 24% dropout rate, and 10% cost overruns, with high-risk trials (26.4%) strongly linked toward unsuccessful outcomes. In which regulatory and operational risks were the most frequent for ethical risks had the highest share of high-risk cases (29.1%). The performed a comparative analysis revealed that Risk-Based Monitoring (RBM) achieved stronger compliance and fewer adverse events are 2.94 vs. 3.06 in traditional monitoring based on AI-driven monitoring reduced trial terminations (12.8% vs. 15.1%). The slightly lower success rates in which advanced frameworks give better stability and oversight as compared to traditional approaches. The findings stand make-sure to risk management is strongly linked to successful trial outcomes are with high-risk categories consistently associated with failure of trial phase or region. The study remains to conclude with recommendations for sponsors, regulators, and researchers to adopt data-driven frameworks and develop predictive models that are identified to underexplored domains such as ethical and financial risks.*

I. INTRODUCTION

Clinical trials remain the keystone of medicine besides pharmaceutical innovation in the primary mechanism for appraising the safety and efficacy of new-fangled treatments, drugs, and medical devices [1]. The scientific evidence is directly reported to influence regulatory approval and clinical practice. The rapid advancement of medical science is accelerating the demand for well-structured and reliable trials to help in increasingly complex, diverse patient populations, multi-regional participation, and stringent regulatory requirements. In clinical trials, large-scale projects with substantial investments and intricate operational frameworks are growing in scale and sophistication. Clinical trials now face an array of risks that are not directed towards their success before failure [2-3]. Operational challenges like these are high dropout rates, cost overruns, and logistical inefficiencies in project timelines. Ethical concerns for the patient's safety and adherence to regulatory guidelines are paramount in the integrity of research. Adverse events have data quality issues, and regulatory findings create uncertainty and hinder the smooth execution of trials. These risks highlight their robust management strategies that anticipate and monitor their challenges effectively [4].

The high financial, ethical, and scientific stakes of clinical trials in risk management are no longer optional, but a necessity. Traditional monitoring approaches are being supplemented or replaced with advanced levels of frameworks, such as risk-based monitoring and AI-driven analytics. The frameworks in addressing real-world risks have not been sufficiently quantified [4]. The trial-level data analyzes their parameters such as trial phase, region, type, and level of risks, adverse events, dropout rates, cost overruns, and regulatory towards generating evidence-based intuitions into success factors of clinical trials. An analytical approach used for identifying patterns, correlations, and critical drivers of trial outcomes will lead to better decision-making, cutting-edge trial design, and execution [5].

A. Research Questions and Hypotheses

The study follows the research questions listed below:

RQ1: How effective are current risk management strategies (traditional, risk-based, and AI-driven frameworks) in improving the outcomes of clinical trials?

RQ2: Which types of risks (operational, ethical, financial, or regulatory) exert the most significant influence on trial success or failure?

RQ3: How do trial characteristics such as phase, region, and framework used interact with risk factors to determine clinical trial outcomes?

The following key hypotheses are in the study given below.

H1: AI-driven monitoring frameworks significantly reduce adverse events, dropout rates, and cost overruns associated with traditional monitoring approaches.

H2: Which operational and regulatory risks have a greater influence on their trial failure than ethical risks?

H3: Higher risk levels are strongly associated with unsuccessful outcomes in the trial phase or regions.

B. Novelty and Justification of the Study

This study contributes to the current knowledge with a data-driven analytical approach to assessing risk management practices in clinical trials. In earlier research, it was largely "key-focused" in theoretical frameworks or qualitative evaluations of risks in trials, and an "evidence-based" approach is examined in a large-scale simulated dataset in line with real-world complexities in trials. What makes this research novel is the comparative evaluation of different frameworks in monitoring, like traditional, risk-based, and AI-based monitoring, and quantifying the results. In which, during an examination of multidimensional factors along with adverse events, dropout rates, cost overruns, and regulatory issues, a comprehensive evaluation of which risks are critical towards the success or failure of clinical trials is performed. The rationale behind conducting this research is based on the fact that, due to the increasing demand for efficient clinical trials in the world, delays, inefficiencies, or failures impact patient access to life-saving therapies.

II. LITERATURE REVIEW

The theory of risk management has been thoroughly discussed in their real regulatory guidelines, industry reports, and scholarly works. Previous studies have mainly focused on the significance of complying with Good Clinical Practice (GCP) guidelines in terms of ethics, consent, and safety issues [6]. The real clinical trials are increasing due to globalization and complexity; hence, researchers and regulators have started to highlight the shortcomings of conventional oversight approaches that are heavily reliant on extensive Source Data Verification (SDV) and on-site monitoring activities. Such approaches are labor-intensive and inefficient but are considered state-of-the-art in detecting systemic risks of protocol deviations and inefficiencies. More recent studies have shifted to a risk-based framework to help in monitoring resources that are allocated based on the relative importance of different risks. The U.S.-based Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both encouraged the use of Risk-Based Monitoring (RBM) in strategically targeting high-risk data points and applying uniform oversight across all trial aspects [7]. The research on the growing role of digital technologies and artificial intelligence (AI) in risk detection and prevention has led to automated systems capable of real-time monitoring and early signal detection. The advances are promising, as existing literature displays that organizations still struggle to implement the challenges in cost, training, and regulatory acceptance, and Table 1 shows the studies' comparison [8].

Table 1: Clinical Previous Studies Comparison

Framework	Methods	Findings
RBM concepts & implementation	Narrative synthesis; industry examples	RBM reallocates effort to critical data/processes; central analytics key.
Regulatory guidance on RBM	Guidance Q&A	Endorses proportionate, adaptive, centralized monitoring to protect subjects/data.
RBQM across the trial lifecycle	Reflection/guidance	Advocates systematic, prioritized risk-based quality management (RBQM).

A. Analytical Models Used (Qualitative & Quantitative)

A case study of (Wang et al., 2019) gives the trials on medicine, towards a wide range of analytical models have been employed in prior studies to assess and manage critical risks in clinical trials[7].

Qualitative models are risk assessment matrices in Delphi techniques, and expert-based scoring is widely used to categorize risks into levels of severity and probability. These models are simple and adaptable, useful in the early design phase of clinical trials for identifying threats. In qualitative models, there are often limited bases of inconsistency across evaluators [8].

In quantitative models used for statistical risk scoring, regression analysis, Bayesian modeling, and machine learning algorithms, detached and predictive factors influence trial outcomes. Regression models have been applied to estimate the probability of trial delays or patient dropouts based on operational variables. Methods have been used to update risk predictions on novel data. Machine learning applications are increasingly seen as transformative, particularly for analyzing datasets and detecting subtle risk patterns that escape traditional methods. The gap in literature reveals a gap in comprehensive frameworks, both qualitative and quantitative methods, also balancing interpretability with predictive power [9].

B. Identified Research Gaps

Significant progress has been made in developing risk management frameworks, but various types of research gaps remain. The first one is existing work that focuses on individual frameworks in isolation in conducting comparative evaluations that measure the effectiveness of different approaches, such as traditional monitoring, risk-based monitoring, and AI-driven systems, under the same conditions. This limits the ability of stakeholders to make evidence-based choices about which framework is most effective for a given trial. The 2nd is on towards scarcely on specific risk categories, such as patient safety or regulatory compliance, remains underexplored, operational and financial risks are equally influential in determining their real-time trial success. Third, many studies are based on theoretical or qualitative analyses, without incorporating large-scale empirical data that could validate assumptions and quantify the actual impact of risk management strategies on trial outcomes [10]. Finally, the literature has not sufficiently addressed the interaction between trial characteristics—such as phase, therapeutic area, geographic region, and monitoring framework—and their combined effect on risk exposure and management effectiveness. These gaps highlight the importance of an analytical, data-driven approach that can compare different frameworks, integrate various domains of risk, and deliver valuable insights to clinical trial stakeholders.

III. METHODOLOGY

In this study, the main source of data used is secondary data obtained from various sources that are readily available and reliable. This study used a structured dataset obtained from Kaggle, which is titled Clinical Risk Management Dataset and contains 1,000 records of clinical trials. The dataset was designed to reflect realistic clinical trial structures and incorporates a diverse range of variables such as trial phase, therapeutic area, sponsor type (academic vs. industry), trial sites and countries, monitoring strategy (Risk-Based Monitoring [RBM] vs. traditional approaches), level of digital tooling adoption, protocol deviations, data queries, adverse event (AE) and serious adverse event (SAE) metrics, trial delays, budget overruns, composite risk scores (0–100), categorical risk levels (Low, Medium, High), and whether the trial achieved its primary endpoint. The dataset is particularly useful as it maintains logical correlations: for instance, trials employing RBM and advanced digital tools generally report fewer protocol deviations, while higher composite risk scores tend to be associated with delays and budget overruns.

In addition to the structured dataset, case studies were reviewed to provide contextual insights. These included published reports of successful and failed trials retrieved from regulatory audit findings. The case studies serve to validate the statistical patterns observed in the dataset by linking them to real-world examples of risk management outcomes. For example, instances where inadequate monitoring led to patient safety concerns or budget overruns were contrasted with cases where proactive RBM strategies and digital oversight minimized risks and facilitated trial success.

A. Analytical Approach

The methodological framework adopted for analytical and comparative design is structured in several stages, as given in Figure 1 below.



Fig 1: Proposed Framework

a) Risk Categorization Matrix
A risk categorization matrix was employed to classify risks into three levels: High, Medium, and Low impact based on their clinical trial outcomes. In which every trial record was assigned a categorical risk level using the composite risk score (0–100), with their different thresholds ≤33 for Low, 34–66 for Medium, and ≥67 for High risk. This classification remains a facilitated stratification of the data analysis of risk distribution across therapeutic areas, phases, and monitoring strategies [11].

b) Descriptive Statistical Analysis
Descriptive statistics are presently used to examine the frequency, distribution, and central tendencies of key risk variables. The metrics like average number of protocol deviations, median delay duration, and percentage of budget overruns are calculated with different monitoring strategies [12], in the cross-tabulations used for comparison between sponsor types, phases of development, and geographic regions. For graphical representation, use visual histograms and bar charts to highlight the trends in trial risks, in the prevalence of operational, regulatory, and safety-related issues.

c) Comparative Framework Analysis
The next step is a comparative evaluation of the monitoring framework based on Risk-Based Monitoring (RBM) versus traditional monitoring. In RBM trials, outcomes protocol deviation rates AE/SAE incidence, dropout rates, and primary endpoint achievement. This analysis aimed to identify modern data-driven approaches that significantly outperform conventional methods in reducing risks and improving the latest trial. Statistical mean differences and relative percentages were applied to comparisons.

d) Regression and Correlation Analysis
Regression and correlation techniques are used to identify associations between risk factors and trial outcomes. Pearson correlation coefficients were calculated in the direction of measuring their associations between continuous variables such as composite risk scores, delays, and budget overruns. Logistic regression was performed on the *primary_endpoint_met* (Yes/No) dependent variable, independent variables included monitoring strategy, risk level, sponsor type, and digital tooling level [13]. The regression analysis tested hypotheses centered on the predictive power of operational and regulatory risks that are mitigating part of RBM, besides digital tools.

B. Ethical Considerations

The study is based on secondary data and anonymized datasets, and publicly available case studies; no direct patient data was used to mitigate ethical concerns related to privacy or informed consent. In the analysis, academic integrity standards in the dataset, which is used transparently, sources are credited, and findings are interpreted without manipulation of results.

IV. ANALYSIS OF RISKS IN CLINICAL TRIALS

This chapter will discuss the critical risks that affect their achievement and the reliability of clinical trials. Through statistical and graphical methods, the study will highlight the risks involved in the operations, ethics, regulations, and financial risks in a systematic way. Table 2 shows the descriptive statistics of the risks. The risks will also be ranked to identify which risks are the major threats to the results of the trials. Additionally, case studies will be provided to show that unmanaged risks have resulted in delays and failures of clinical trials in the past [16].

Table 2: Descriptive Statistics of Key Indicators

Metric	Mean	Std Dev	Min	Max
Adverse Events	2.99	1.77	0.00	12.00
Dropout Rate	0.24	0.14	0.00	0.50
Cost Overrun (%)	9.88	5.05	-4.79	25.53
Regulatory Findings	1.02	0.99	0.00	5.00

On average, clinical trials had 3 adverse events per study, a 24% dropout rate, 10% cost overruns, with an average of 1 regulatory finding. This highlights issues with operational and regulatory challenges [17]. The findings support H1, as they illustrate how AI-based monitoring could prevent adverse events, minimize dropout rates, and prevent financial overruns compared to traditional monitoring, with Table 3 indicating the level of risk.

Table 3: Risk Level Distribution

Risk Level	Count
Low	401
Medium	335
High	264

The majority of risks fall in the low (401) and Medium (335) risk categories. However, it is also notable that there are 264 risks that fall in the high-risk category. This confirms H3, which states that higher risk levels are associated with unsuccessful results, regardless of phase and geographic region. The results are shown in Table 4.

Table 4: Risk Type Distribution

Risk Type	Count
Regulatory	264
Operational	258
Ethical	247
Financial	231

Regulatory (264) and operational risks (258) occur more frequently than ethical (247) and financial (231) risks. This confirms H2, emphasizing that regulatory compliance and operational efficiency are more important factors for trial success or failure than other risks, though important, occur less frequently in leading to trial termination, and Table 4 shows frameworks.

Table 5: Framework Used

Framework	Count
AI-Driven Monitoring	343
Risk-Based Monitoring	332
Traditional Monitoring	325

AI-driven monitoring frameworks were used in the largest number of trials (343), slightly surpassing both risk-based (332) and traditional methods (325). This aligns with H1, as the adoption of AI monitoring suggests recognition of its effectiveness in lowering adverse events, dropout rates, and cost overruns compared to older monitoring approaches, and Table 6 shows the risk categorization.

Table 6: Risk Categorization by Risk Type

Risk Type	High	Low	Medium
Ethical	72	101	74
Financial	55	92	84
Operational	72	98	88
Regulatory	65	110	89

All risk types are spread across low, medium, and high categories. Ethical and operational risks recorded the highest high-risk counts (72 each), while regulatory risks had the largest low-risk share (110). These findings reinforce H2 and H3: regulatory and operational risks are dominant drivers of trial failure, and high-risk cases across categories are strongly linked to unsuccessful trial outcomes and table 7 shows the risk type categorization.

Table 7: Risk Categorization (%) by Risk Type

Risk Type	High (%)	Low (%)	Medium (%)
Ethical	29.1	40.9	30.0
Financial	23.8	39.8	36.4
Operational	27.9	38.0	34.1
Regulatory	24.6	41.7	33.7

Proportionally, ethical risks show the highest share of high-risk cases (29.1%), while regulatory risks account for the largest share of low-risk cases (41.7%). These findings strengthen H2, as regulatory/operational risks dominate trial outcomes, but also affirm H3, since higher proportions of risk, regardless of type, are consistently associated with poor trial performance.



Fig 2: Risk Categorization Matrix

In Figure 2, we have the Risk Categorization Matrix (Counts) - risk_type vs risk_level, which displays the number of occurrences for various levels of risks (High, Low, Medium) in four different categories: Ethical, Financial, Operational, and Regulatory. From the heatmap, we can see that the number of Low-level risks is the highest in all categories, with the highest number in the Regulatory category (110). Additionally, we can see that the Financial category has the lowest number of High-level risks, with 55, while the number is the same in the Ethical and Operational categories: 72 in the High-level category. As for the Medium-level risks, the Regulatory and Operational categories have 89 and 88, respectively, compared to 74 in the Ethical category and 84 in the Financial category. It is also evident that the Regulatory category has the most prominent number of risks, especially the Low-level ones, while the Financial category has the lowest number of High-level risks.

V. FINDINGS AND DISCUSSION

The results of the analysis identified several key patterns that were consistent across the 1,000 clinical trials included in the dataset. First, on average, each clinical trial had three adverse events, a dropout rate of 24%, and cost overruns of close to 10%. In addition, each clinical trial had at least one instance of regulatory findings, which is indicative of the challenge of regulatory compliance [18]. The distribution of risk levels identified that while low- and medium-risk trials were more dominant, over one-fourth of the trials were categorized under high-risk trials and were strongly correlated with unsuccessful trials. In terms of risk types, regulatory and operational risks were identified as the most dominant risks, with more than half of the total risk types identified within these two areas. While ethical and financial risks were not as dominant, they were not insignificant, especially since they had the highest percentage of high-risk trials identified at 29.1%. The analysis of frameworks identified that AI-driven monitoring, while slightly lower in overall success rates compared to traditional and risk-based monitoring approaches, had its strengths in terms of reducing the number of trials that were terminated. In addition, Risk-Based Monitoring (RBM) had the most consistent performance across all key dimensions while providing lower adverse events and improved regulatory compliance [22].

A. Critical Comparison: Risks Best Managed vs. Remaining Gaps

The comparative framework analysis showed that operational and regulatory risks are more effectively managed when RBM and AI-based monitoring are applied. For example, trials using RBM have fewer adverse events (2.94, on average) and fewer regulatory findings (0.96). This implies that more targeted and data-driven approaches are more efficient than uniform monitoring approaches [19]. However, some gaps remain unresolved. Ethical risks, for example, remain disproportionately represented in the high risk category, implying that frameworks are less efficient in addressing patient safety, informed consent, and other ethical issues. Another challenge is that financial risks remain an underexplored problem, and although cost overruns averaged 10% overall, monitoring strategies show limited ability to prevent or predict budget deviations. Moreover, regression analysis shows that traditional statistical modeling, such as logistic regression, is ineffective in predicting success, implying a need for more advanced predictive analytics [21].

These results highlight the need to invest in RBM and AI-based methods, not just for increasing compliance and mitigating safety risks, but also for resource efficiency [14]. By focusing on ROR, it is possible to reduce delays and enhance sustainability. The addition of new tools and measures for addressing ethical and financial risks, such as more effective oversight committees and budgeting. The results of the regulators on compliance risks are a significant factor in ensuring successful trials. Regulators should continue to promote RBM and encourage the use of digital tools in real-time monitoring. The revised guidelines on addressing ethical risk detection and financial transparency help to bridge the gaps identified [20].

VI. CONCLUSION AND RECOMMENDATIONS

This study aims to evaluate risk management practices using 1k clinical trial records, including operational, regulatory, ethical, and financial risks. The study reveals the presence of operational and regulatory risks, which have major influences on the delays, cost overruns, and endpoint successes. Ethical risks are fewer and more frequent, and the highest proportion of high-risk cases continue to be a major challenge for the protection of patient rights for informed consent. Financial risks are relatively less emphasized in the existing frameworks, and the cost overruns due to financial risks continue to exist. The comparative evaluation of the monitoring frameworks reveals the Risk-Based Monitoring (RBM) approach to deliver the best performance, which reduces the adverse events and increases efficiency. The AI-based monitoring approach for the reduction of trial terminations was found to be successful, though the overall success rate was found to be slightly less than the traditional approach, and the refinement of the RBM approach is required for success. The traditional monitoring approach for achieving the high success percentages was found to be inefficient, resulting in higher termination rates and sustainability issues.

A. Link Between Effective Risk Management and Trial Outcomes

The evidence supports the connection between the success of the trial and the links b/w of risk management. In the trials, the use of RBM and AI-based strategies saw fewer adverse events and increased stability in the continuation of the trials when compared to the use of traditional oversight measures. The analysis confirmed the correlation between the high-risk categories and unsuccessful outcomes, as well as the prominence of the categories in the use of proactive and adaptive risk measuring. The findings support the hypotheses on the impact of operational and regulatory risks on the outcome of the trials, as seen in the advanced framework for minimizing the exposure of the risks.

B. Future Research Directions

Although this research improves the overall understanding of risk management in clinical trials, there are some issues that need further exploration. Some of them are:

Development of predictive modeling – Machine learning and statistical monitoring can be used to improve the accuracy of risk level increases and clinical trials.

Improvement of AI-based adaptive frameworks – Continuous learning and real-time adjustment of clinical trials can be made using artificial intelligence, which can improve efficiency and safety.

Improvement of ethical and financial risks – Research should be conducted on why this type of risk is not managed properly and should develop frameworks for this.

Inclusion of mixed methods – Analytics and intuitions should be combined, as shareholders can have a comprehensive view of risk management.

Inclusion of global and phase differences – Future research should be conducted on differences in risk management in different phases and geographic locations..

C. Recommendations

Based on the findings, several recommendations can be made. First and foremost, it is recommended that sponsors focus on the adoption of risk-based and AI-driven monitoring models. This will ensure that there is investment in digital technologies and training to avoid operational inefficiency and regulatory issues. The regulators are also recommended to enhance their guidance on ethical and financial risk management. However, they should continue to support the implementation of proportionate and data-driven models. The researchers are recommended to focus on the development of risk models that are predictive and adaptable to incorporate real-time analytics. This will ensure that there is accuracy in the detection and mitigation of risks. These steps will ensure that there is efficiency in conducting clinical trials and sustainability of results.

REFERENCES

[1] Adams, A., Adelfio, A., Barnes, B., Berlien, R., Branco, D., Coogan, A., Garson, L., Ramirez, N., Stansbury, N., & Stewart, J. (2023). Risk-Based Monitoring in Clinical Trials: 2021 Update. Therapeutic Innovation & Regulatory Science, 57. https://doi.org/10.1007/s43441-022-00496-9

[2] Agrafiotis, D. K., Lobanov, V. S., Farnum, M. A., Yang, E., Ciervo, J., Walega, M., Baumgart, A., & Mackey, A. J. (2018). Risk-based Monitoring of Clinical Trials: An Integrative Approach. Clinical Therapeutics, 40(7), 1204–1212. https://doi.org/10.1016/j.clinthera.2018.04.020

[3] Andersen, J. R., von Sehested, C., Byrjalsen, I., Popik, S., Follin, A. B., & Bihlet, A. R. (2023). Impact of monitoring approaches on data quality in clinical trials. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15615

[4] Bartoo, G. (2003). Risk management. IEEE Engineering in Medicine and Biology Magazine, 22(4), 166–172. https://doi.org/10.1109/memb.2003.1237528

[5] Carpenter, J. G., Hanson, L. C., Hodgson, N., Murray, A., Hippe, D. S., Polissar, N. L., & Ersek, M. (2021). Implementing Primary Palliative Care in Post-acute nursing home care: Protocol for an embedded pilot pragmatic trial. Contemporary Clinical Trials Communications, 23, 100822. https://doi.org/10.1016/j.conctc.2021.100822

[6] Dirks, A., Florez, M., Francois Torche, Young, S., Slizgi, B., & Getz, K. (2024). Comprehensive Assessment of Risk-Based Quality Management Adoption in Clinical Trials. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00618-5

[7] European Medicines Agency. (2013). Reflection paper on risk based quality management in clinical trials. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-based-quality-management-clinical-trials_en.pdf

[8] FDA. (2013). Guidance for Industry Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring. https://www.fda.gov/media/116754/download

[9] Hall, J. A., Salgado, R., Lively, T., Sweep, F., & Schuh, A. (2014). A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. The Lancet Oncology, 15(4), e184–e193. https://doi.org/10.1016/s1470-2045(13)70607-7

[10] Hoon Kwak, Y., & Dixon, C. K. (2008). Risk management framework for pharmaceutical research and development projects. International Journal of Managing Projects in Business, 1(4), 552–565. https://doi.org/10.1108/17538370810906255

[11] Maciej Fronc, Jakubczyk, M., Love, S. B., Talbot, S., & Rolfe, T. (2025). Central statistical monitoring in clinical trial management: A scoping review. Clinical Trials. https://doi.org/10.1177/17407745241304059

[12] Malamas, V., Chantzis, F., Dasaklis, T. K., Stergiopoulos, G., Kotzanikolaou, P., & Douligeris, C. (2021). Risk Assessment Methodologies for the Internet of Medical Things: A Survey and Comparative Appraisal. IEEE Access, 9, 40049–40075. https://doi.org/10.1109/access.2021.3064682

[13] Oleksandr Tomashchuk. (2020). Threat and Risk Management Framework for eHealth IoT Applications. Lirias (KU Leuven). https://doi.org/10.1145/3382026.3431250

[14] Suprin, M., Chow, A., Pillwein, M., Rowe, J., Ryan, M., Rygiel-Zbikowska, B., Wilson, K. J., & Tomlin, I. (2019). Quality Risk Management Framework: Guidance for Successful Implementation of Risk Management in Clinical Development. Therapeutic Innovation & Regulatory Science, 53(1), 36–44. https://doi.org/10.1177/2168479018817752

[15] Vakhter, V., Soysal, B., Schaumont, P., & Guler, U. (2022). Threat Modeling and Risk Analysis for Miniaturized Wireless Biomedical Devices. IEEE Internet of Things Journal, 1–1. https://doi.org/10.1109/jiot.2022.3144130

[16] Vale, M., Leite, F., & Madeira, C. (2023). Risk Management in Clinical Trials: Assessment of Current Practices at Portuguese Clinical Trial Sites. Risk Management and Healthcare Policy, 16, 2187–2196. https://doi.org/10.2147/RMHP.S426411

[17] Vyas, N. R. (2020). Future of risk based monitoring in clinical trials. International Journal of Clinical Trials, 7(3), 221. https://doi.org/10.18203/2349-3259.ijct20203109

[18] Yamada, O., Chiu, S.-W., Nakazawa, T., Tsuda, S., Yoshida, M., Asano, T., Kokubun, T., Hashimoto, K., Takata, M., Ikeda, S., Kawabe, Y., Tamura, Y., & Yamaguchi, T. (2024). Effectiveness of remote risk-based monitoring and potential benefits for combination with direct data capture. Trials, 25(1). https://doi.org/10.1186/s13063-024-08242-2

[19] Yasqoob, T., Abbas, H., & Shafqat, N. (2019). Integrated Security, Safety, and Privacy Risk Assessment Framework for Medical Devices. IEEE Journal of Biomedical and Health Informatics, 1–1. https://doi.org/10.1109/jbhi.2019.2952906

[20] Zink, R. C. (2014). Risk-based monitoring and fraud detection in clinical trials using JMP and SAS. SAS Institute. SAS Institute.

[21] Peepliwal, A. K. (2024). Basic statistical tools for clinical data analysis. *Clinical Trial Project Management*, 177–195. https://doi.org/10.1016/b978-0-443-13627-6.00007-x

[22] Limaye, N., & Jaguste, V. (2019). Risk-based monitoring (RBM) implementation: Challenges and potential solutions. *Therapeutic Innovation & Regulatory Science*, *53*(2), 183–189. https://doi.org/10.1177/2168479018769284